Sanofi challenges Amgen’s patents for cholesterol-lowering antibodies

Chris Burgess 2022-10-18 5:23 pm By Sam Matthews | Melbourne

Please login to bookmark

French drug giant Sanofi has appealed a decision giving American biopharmaceutical company Amgen the go-ahead for its patents for a cholesterol-lowering antibody that could be used to treat heart disease, diabetes, stroke and Alzheimer’s.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au